Tempus AI Reports >80% Sensitivity for NSCLC AI Pre-Screen
Tempus said its H&E pre-screening panel showed >80% sensitivity across 12 biomarkers, with several above 90%, in an analysis of 60,459 cases presented at ESMO 2026. The tool is in development and intended to prioritize confirmatory testing.